Acumen Pharmaceuticals Inc
ABOS
Company Profile
Business description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Contact
1210-1220 Washington Street
Suite 210
NewtonMA02465
USAT: +1 617 344-4190
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
61
Stocks News & Analysis
stocks
ASX tech share upgraded following AI contract wins
Strong demand for AI infrastructure drives fair value lift.
stocks
5 star fully franked ASX dividend payer
Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,969.20 | 82.60 | 0.93% |
| CAC 40 | 7,986.33 | 49.54 | -0.62% |
| DAX 40 | 25,311.57 | 87.64 | -0.35% |
| Dow JONES (US) | 51,349.92 | 131.59 | -0.26% |
| FTSE 100 | 10,630.25 | 6.46 | -0.06% |
| HKSE | 24,613.27 | 89.70 | 0.37% |
| NASDAQ | 26,797.54 | 22.84 | -0.09% |
| Nikkei 225 | 66,753.72 | 1,272.45 | 1.94% |
| NZX 50 Index | 13,834.39 | 150.76 | 1.10% |
| S&P 500 | 7,670.84 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,789.30 | 80.00 | 0.92% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |